10-K Decoder · All companies

Inhibrx Biosciences, Inc.

INBX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$1.30M$200K+550%
Operating income−$135M−$331M+59.3%
Net income−$140M$1.69B

Questions

What was Inhibrx's revenue in FY2025?
$1.30M in FY2025 (Fiscal year ended Dec 31, 2025), +550% vs $200K a year earlier, per its 10-K filed Mar 2026.
Was Inhibrx profitable in FY2025?
No: net income was −$140M and operating income −$135M in FY2025.